Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Curis, Inc. CRIS
$0.93
+$0.02 (2.43%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
88956104.00000000
-
week52high
1.77
-
week52low
0.47
-
Revenue
10162000
-
P/E TTM
-1
-
Beta
2.92975700
-
EPS
-0.62000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 20:00
Описание компании
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Raymond James | Market Perform | Outperform | 05 апр 2022 г. |
| B. Riley Securities | Buy | Buy | 05 апр 2022 г. |
| Raymond James | Outperform | 13 окт 2021 г. | |
| B. Riley FBR | Buy | 25 мар 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 15 янв 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 10 ноя 2022 г. |
| B. Riley Securities | Buy | 25 мар 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Hohneker John | A | 85000 | 85000 | 23 янв 2023 г. |
| KAITIN KENNETH I | A | 85000 | 85000 | 23 янв 2023 г. |
| GREENACRE MARTYN D | A | 85000 | 85000 | 23 янв 2023 г. |
| Rubin Marc | A | 85000 | 85000 | 23 янв 2023 г. |
| Borgman Anne Elizabeth | A | 85000 | 85000 | 23 янв 2023 г. |
| Martell Robert | A | 350000 | 350000 | 20 янв 2023 г. |
| Duvall Diantha | A | 500000 | 500000 | 20 янв 2023 г. |
| Dentzer James E | A | 1000000 | 1000000 | 20 янв 2023 г. |
| Borgman Anne Elizabeth | A | 25000 | 25000 | 12 окт 2022 г. |
| Kunkel Lori Anne | A | 85000 | 85000 | 31 янв 2022 г. |
Новостная лента
Curis (CRIS) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research
04 мая 2023 г. в 19:01
Curis (CRIS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.18 per share a year ago.
Curis to Present at Upcoming Healthcare Conferences in April
PRNewsWire
03 апр 2023 г. в 08:00
LEXINGTON, Mass. , April 3, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences: The Cantor Fitzgerald Future of Oncology Symposium, being held virtually from April 3 – 5, 2023.
Curis, Inc. (CRIS) Q4 2022 Earnings Call Transcript
Seeking Alpha
13 мар 2023 г. в 12:22
Curis, Inc. (NASDAQ:CRIS ) Q4 2022 Earnings Conference Call March 13, 2023 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer James Dentzer - President and Chief Executive Officer Robert Martell - Head of R&D Conference Call Participants Ed White - H.C. Wainwright Soumit Roy - JonesTrading Yale Jen - Laidlaw & Company Operator Good morning, and welcome to the Curis Fourth Quarter 2022 Business Update Call.
Curis (CRIS) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
13 мар 2023 г. в 10:44
Curis (CRIS) delivered earnings and revenue surprises of 14.29% and 4.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call
PRNewsWire
08 мар 2023 г. в 19:09
LEXINGTON, Mass. , March 8, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today that it is rescheduling its fourth quarter business update and quarterly investor conference call previously scheduled for Thursday, March 9, 2023 at 4:30 p.m.